Contraindications of incretin therapy: difference between revisions

Diff·revision 7 → 8·03:07, 2 Feb 2025

Difference between revision 7 and revision 8 of Contraindications of incretin therapy. 11 lines changed; the page grew by 721 bytes.

Revision 7 — 19:24, 12 Jan 2025 PuffRemoverPax (talk) add the note that titration exists partly to manage these effects 2,653 bytes ±0	Revision 8 — 03:07, 2 Feb 2025 ResinRhoswen (talk) correct the renal statement — the caution is about volume depletion 3,374 bytes +721
19	Product labels also carry a substantial set of warnings that are not contraindications — pancreatitis, gallbladder disease, retinopathy in the context of rapid glycaemic improvement, and the perioperative considerations discussed at [[Aspiration risk under anaesthesia]].{{r\|ada2024}}	19	Product labels also carry a substantial set of warnings that are not contraindications — pancreatitis, gallbladder disease, retinopathy in the context of rapid glycaemic improvement, and the perioperative considerations discussed at [[Aspiration risk under anaesthesia]].{{r\|ada2024}}
20		20
+		21	== Cautions and interactions ==
+		22	\| Circumstance \| Consideration \|
+		23	\|---\|---\|
+		24	\| Concurrent insulin or sulfonylurea \| Reduce the background agent; hypoglycaemia risk \|
+		25	\| Severe gastroparesis \| Delayed emptying may worsen symptoms \|
+		26	\| Prior pancreatitis \| Causality unestablished; caution conventional \|
+		27	\| Pregnancy or planning \| Not recommended; weight loss undesirable in pregnancy \|
+		28	\| Severe renal impairment \| Dehydration from vomiting can precipitate injury \|
+		29
+		30	Renal considerations are indirect for most of this class: the peptides are not renally cleared to a degree requiring dose adjustment, but persistent vomiting and reduced intake can precipitate acute kidney injury in someone with limited reserve.{{r\|ada2024}}
+		31
21	== References ==	32	== References ==
22	{{reflist}}	33	{{reflist}}